References
- Krecak I, Lucijanic M, Verstovsek S. Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep. 2022;17(5):155–169. doi:10.1007/s11899-022-00670-8
- Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599–1613. doi:10.1002/ajh.26008
- Krecak I, Verstovsek S, Lucijanic M. Optimization of cardiovascular risk factor management in patients with BCR:ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives. Ann Hematol. 2023; doi:10.1007/s00277-023-05426-9
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. 19 doi:10.1182/blood-2016-03-643544
- ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19–s40. doi:10.2337/dc23-S002
- Leung E, Wongrakpanich S, Munshi MN. Diabetes management in the elderly. Diabetes Spectr. 2018;31(3):245–253. doi:10.2337/ds18-0033
- Gao QY, Zhu YM, Hu J[, et al. Red blood cell lifespan detected by endogenous carbon monoxide breath test in patients with polycythemia vera. ]. Zhonghua Nei Ke Za Zhi. 2019;58(10):777–781.
- Ren Q, Lv X, Yang L, et al. Erythrocytosis and performance of HbA1c in detecting diabetes on an oxygen-deficient plateau: a population-based study. J Clin Endocrinol Metab. 2020;105(4)